

PRESS RELEASE

Date 12 April 2017

Contact Media Relations, Vifor Pharma Group: Beatrix Benz, Head of Global Communications & Public Affairs
Investor Relations, Vifor Pharma Group: Julien Vignot, Head of Investor Relations

Subject Galenica Santé IPO – Full exercise of over-allotment option

Galenica Santé IPO – Full exercise of over-allotment option

On 7 April 2017, the shares of Galenica Santé, the leading fully-integrated healthcare provider in Switzerland, were listed and admitted to trading on SIX Swiss Exchange. Today, the Joint Global Coordinators, acting on behalf of the syndicate banks, have exercised the over-allotment option in full.

On 7 April 2017, the shares of Galenica Santé (SIX: GALE) were listed and admitted to trading on SIX Swiss Exchange. The Joint Global Coordinators, acting on behalf of the syndicate banks, have today exercised the full over-allotment option consisting of 6,358,700 shares at CHF 39.00 per share, representing 15% of the 42,391,300 shares offered in the base offering, corresponding to a total amount of nearly CHF 248 million. Therefore, the stabilisation period has ended on 12 April 2017.

Including the shares placed in connection with the over-allotment option, Galenica Ltd. (SIX: VIFN) has sold a total of 48,750,000 shares in the IPO of Galenica Santé, which corresponds to 97.5% of the share capital. The remaining shares, amounting to 2.5% of the share capital of Galenica Santé, are reserved for the exchange of Galenica Group shares into Galenica Santé shares for eligible employees of Galenica Santé.

The strong demand led to the order book being several times oversubscribed, accordingly, the subscription offers for many investors could not be taken into account as desired. Shares were allocated based on the customary objective criteria in an IPO, resulting in the targeted broadly-diversified shareholder base, comprising some 50% Swiss retail and institutional and around 50% international institutional investors.

Citigroup, Credit Suisse and UBS acted as Joint Global Coordinators and Joint Bookrunners in the context of the IPO. Deutsche Bank also acted as a Joint Bookrunner. Baader Bank, Bank am Bellevue, Bank Vontobel AG and Zürcher Kantonalbank acted as Co-Lead Managers. Centerview Partners acted as the independent financial advisor to Galenica.

At the Annual General Meeting of Galenica Ltd. on 11 May 2017, shareholders will vote on the name change of Galenica Group to Vifor Pharma Group. As a result it is expected that as of 12 May 2017, Galenica Santé will be renamed Galenica.

Vifor Pharma Group includes the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (VFMCRP), its joint company with Fresenius Medical Care; Relypsa; and OM Pharma.

More information on the separation can be found on the Galenica/Vifor Pharma website:
<http://www.galenica-viforpharma.com> or <http://www.viforpharma.com>.

For further information, please contact:

Media Relations

Beatrix Benz
Head of Global Communications & Public Affairs
Tel.: +41 58 851 80 16
E-mail: media@viforpharma.com

Investor Relations

Julien Vignot
Head of Investor Relations
Tel.: +41 58 851 66 90
E-mail: investors@viforpharma.com

Vifor Pharma Group, formerly **Galenica Group**, is a global specialty pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for specialty pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group, headquartered in Zurich, Switzerland, holds a leading position in all their core business activities. Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, security number 1,553,646). For more information, visit www.viforpharma.com.

Disclaimer

This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. This document is not a prospectus within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. A decision to invest in securities of Galenica Santé AG (the "Company") should be based exclusively on the issue and listing prospectus to be published by the Company for such purpose.

This document and the information contained herein are for information purposes only and do not constitute a prospectus or an offer to sell, or a solicitation of an offer to buy, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or pursuant to an available exemption from registration under the Securities Act. Neither Galenica Santé AG (the "Company") nor its shareholder intends to register any securities referred to herein in the United States.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is being communicated only to (i) persons who are outside the U.K.; (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (iii) high net worth companies, unincorporated associations and other bodies who fall within article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This document should not be published, reproduced, distributed or otherwise made available, in whole or in part, to any other person without the prior consent of the Company.

Date 12 April 2017
Page 3/3
Subject Galenica Santé IPO – Full exercise of over-allotment option

Any offer of securities to the public that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an “EEA Member State”) that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the “Prospectus Directive”) is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.

The Joint Bookrunners and Co-Lead Managers are acting exclusively for the Company and no-one else in connection with the Offering. They will not regard any other person as their respective clients in relation to the Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the Offering, the contents of this announcement or any transaction, arrangement or other matter referred to herein.

This document contains forward-looking statements. These statements are based on the current views, expectations, assumptions and information of the management of the Company. Forward-looking statements should not be construed as a promise of future results and developments and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those described in such statements due to a number of factors. The Company does not assume any obligations to update any forward-looking statements.